1
2
#OpenInnovation
3
4
News & Events
Imago Granted Access by EMA to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis
July 30, 2020
Access granted on positive primary analysis of the ongoing Phase 2 trial. Read more
Imago Biosciences: Experimental Treatment for Rare Bone Cancer Shows Promise in Phase 2 Study
June 17, 2020
RARE Daily's Marie Daghlian spoke with Hugh Rienhoff, CEO of Imago Biosciences. Read more
GreenLight Biosciences supercharges its efforts with $102M Series D funding
June 16, 2020
New funding builds on company's current efforts to bring sustainable biopesticides and a COVID-19 vaccine to market. Read more
5
#knowledgebase
6
7
News & Events
Imago Granted Access by EMA to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis
July 30, 2020
Access granted on positive primary analysis of the ongoing Phase 2 trial. Read more
Imago Biosciences: Experimental Treatment for Rare Bone Cancer Shows Promise in Phase 2 Study
June 17, 2020
RARE Daily's Marie Daghlian spoke with Hugh Rienhoff, CEO of Imago Biosciences. Read more
GreenLight Biosciences supercharges its efforts with $102M Series D funding
June 16, 2020
New funding builds on company's current efforts to bring sustainable biopesticides and a COVID-19 vaccine to market. Read more
8
Portfolio Highlights
#PharmaBiotech
11
Our View
10
Our Focus
12
#PRI
22
Medical Technologies
#Portfolio
14
Life is resilient,
together we will
endure
#StayAtHome
#BreakTheChain
#FlattenTheCurve
16
Words from
the CEO
17
Portfolio Highlights
#PharmaBiotech
28
Pharmaceutical Biotech
#Portfolio
15
About Us
34
Biorenewables & Others
#Portfolio
19
WHAT'S TRENDING @ XERAYA
EMA Grants Imago's Bomedemstat to PRIME Scheme
20
Our Team
21
23
Portfolio Highlights
#Biorenewables
30
Portfolio Highlights
#MedTech
25
26
ARE YOU
The Next
Big Thing?
Submit
A
Proposal
29
36
Career
#Xeraya
35
37
News & Events
Imago Granted Access by EMA to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis
July 30, 2020
Access granted on positive primary analysis of the ongoing Phase 2 trial. Read more
Imago Biosciences: Experimental Treatment for Rare Bone Cancer Shows Promise in Phase 2 Study
June 17, 2020
RARE Daily's Marie Daghlian spoke with Hugh Rienhoff, CEO of Imago Biosciences. Read more
GreenLight Biosciences supercharges its efforts with $102M Series D funding
June 16, 2020
New funding builds on company's current efforts to bring sustainable biopesticides and a COVID-19 vaccine to market. Read more
32
#agro
33
Portfolio Highlights
#Biorenewables
38
Portfolio Highlights
#MedTech
39
40
Contact Us
41
